Ambrx Biopharma American Stock Price To Sales
| AMAMDelisted Stock | USD 15.73 0.71 4.73% |
Ambrx Biopharma American fundamentals help investors to digest information that contributes to Ambrx Biopharma's financial success or failures. It also enables traders to predict the movement of Ambrx Stock. The fundamental analysis module provides a way to measure Ambrx Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ambrx Biopharma stock.
Ambrx |
Ambrx Biopharma American Company Price To Sales Analysis
Ambrx Biopharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Ambrx Biopharma Price To Sales | 432.96 X |
Most of Ambrx Biopharma's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ambrx Biopharma American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Ambrx Biopharma American has a Price To Sales of 432 times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.
Ambrx Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ambrx Biopharma's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics of similar companies.Ambrx Biopharma is currently under evaluation in price to sales category among its peers.
Ambrx Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (483.51) % | |||
| Current Valuation | 1.56 B | |||
| Shares Outstanding | 63.29 M | |||
| Shares Owned By Insiders | 2.09 % | |||
| Shares Owned By Institutions | 97.91 % | |||
| Number Of Shares Shorted | 1.16 M | |||
| Price To Earning | 0.19 X | |||
| Price To Book | 7.31 X | |||
| Price To Sales | 432.96 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 7.4 M | |||
| EBITDA | (61.75 M) | |||
| Net Income | (67.06 M) | |||
| Cash And Equivalents | 110.89 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.98 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 4.70 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (57.7 M) | |||
| Short Ratio | 1.21 X | |||
| Earnings Per Share | 0.42 X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 28.5 | |||
| Number Of Employees | 87 | |||
| Beta | -2.36 | |||
| Market Capitalization | 1.77 B | |||
| Total Asset | 146.98 M | |||
| Retained Earnings | (291.63 M) | |||
| Working Capital | 73.92 M | |||
| Z Score | 85.23 | |||
| Net Asset | 146.98 M |
About Ambrx Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ambrx Biopharma American's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ambrx Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ambrx Biopharma American based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |